HIV Infections Clinical Trial
Official title:
Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other Infections
To correlate HIV-1 viral load in vaginocervical secretions (VCS), as measured by culture and
nucleic acid detection, with that found in peripheral blood and HIV clinical status. To
determine whether systemic and local HIV specific antibody influences the quality and type
of virus isolated from VCS. To ascertain whether the presence of specific infectious agents
(e.g., HPV, HSV, CMV, etc.) influences the amount and type of virus isolated from VCS.
Predictors for the development of the acquired immunodeficiency syndrome (AIDS) in HIV
infected individuals have been studied primarily among adult males and in selected small
populations. Although many of these predictors may be relevant to women, HIV infection does
manifest itself differently between the sexes. Therefore, it is important to study the
spectrum of HIV disease in women and to identify unique and common markers, cofactors, and
predictors of disease progression.
Predictors for the development of the acquired immunodeficiency syndrome (AIDS) in HIV
infected individuals have been studied primarily among adult males and in selected small
populations. Although many of these predictors may be relevant to women, HIV infection does
manifest itself differently between the sexes. Therefore, it is important to study the
spectrum of HIV disease in women and to identify unique and common markers, cofactors, and
predictors of disease progression.
Part 009: HIV-infected female adults, independent of CD4+ cell count, will provide blood and
VCS specimens obtained at a single study visit, regardless of ovulatory phase.
NOTE: Subjects in this study will be patients who are currently enrolled in a multisite
longitudinal study, Women's Interagency HIV Study (WIHS), which is designed to elucidate the
natural history of infection with HIV-1 in U.S. women. Participation in DATRI 009 will
require additional blood at the patient's scheduled WIHS visit.
Part 009a: Consent will be obtained from 65 women to allow additional evaluations to be
completed on their reserve VCS specimen and on an additional peripheral blood specimen,
specifically obtained for DATRI 009a during their 009 visit. An additional 8 ml CPT tube
will be collected from these patients, bringing their total blood volume to 32 ml at their
scheduled WIHS visit.
;
Observational Model: Natural History
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |